RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
159 hedge funds and large institutions have $706M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2022 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 39 increasing their positions, 47 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
16% less capital invested
Capital invested by funds: $841M → $706M (-$135M)
17% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 47
Holders
159
Holding in Top 10
2
Calls
$46M
Puts
$28.1M
Top Buyers
| 1 | +$45.5M | |
| 2 | +$26.5M | |
| 3 | +$18.2M | |
| 4 |
FAM
Fred Alger Management
New York
|
+$15.4M |
| 5 |
Millennium Management
New York
|
+$11.8M |
Top Sellers
| 1 | -$61.3M | |
| 2 | -$48.7M | |
| 3 | -$25.1M | |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$19.7M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.1M |